With star checkpoint inhibitors like Keytruda and Opdivo now sporting subcutaneous formulations, GSK has struck a deal aimed ...

GSK plc to acquire RAPT Therapeutics Inc. for $58.00 per share, with an estimated upfront investment of $1.9 billion.

That price equates to an aggregate equity value of $2.2 billion, according to GSK, who added that the upfront investment net ...

By Pushkala Aripaka and Bhanvi Satija Jan 20 (Reuters) - Britain's GSK has agreed to buy RAPT Therapeutics for $2.2 billion, ...

The star of the acquisition, anti-IgE antibody ozureprubart, is being tested as a prophylactic treatment for food allergies, ...

GSK has agreed to acquire RAPT Therapeutics, adding food allergy drug candidates to its pipeline. The company has received ...

The acquisition will strengthen GSK’s immunology pipeline, which is a key area of focus for the pharma company.

Bristol Myers Squibb, GSK and Merck are contributing drug ingredients as part of their deals with the White House but are ...

Nisha Gopalan is a former Senior Overnight Assignment Editor for Investopedia News. She is an award-winning financial journalist who has worked in London, where she is currently based, and Hong Kong.

UK pharma major GSK today announced that its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine, Arexvy, has ...

The New York powerhouse has agreed to surrender its 11.7% interest in the HIV-focused company for $1.875 billion. Under terms ...

GSK acquires Rapt Therapeutics for $2.2B. Stock surges 65% as pharma giant gains access to phase 2b food allergy treatment ...